Boston Scientific
BSX
41.58
-0.61
-1.45%
Boston Scientific
US · BSX
#364 by market cap
Listed 1970
41.58
-0.61
-1.45%
Live - 5344 symbols - heartbeat 82s ago
· 2026-10-08 07:00
Pre-market
41.57
-0.02%
After-hours
41.70
+0.29%
Overnight
41.64
+0.14%
- Market cap
- 60.26B
- P/E (TTM)i
- 16.83
- P/Bi
- 2.42
- EPSi
- 1.94
- Div yieldi
- 0.00%
- 52W posi
- 0%
Reader sentiment
Are you bullish or bearish on BSX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.91, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +19.87% YoY
Margins
- Gross margin
- 69.01%
- Operating margin
- 19.78%
- Net margin
- 14.44%
Key ratios & quality
- Enterprise valuei
- 69.60B
- PEG ratioi
- 0.28
- Altman Z-Scorei
- 2.91
PEG uses trailing P/E against the 3-year net income growth rate (60.72%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.82B | 10.74B | 9.91B | 11.89B | 12.68B | 14.24B | 16.75B | 20.07B |
| Gross profit | 6.94B | 7.55B | 6.40B | 8.18B | 8.73B | 9.90B | 11.49B | 13.85B |
| Selling & admin expenses | 3.57B | 3.94B | 3.79B | 4.36B | 4.52B | 5.19B | 5.98B | 6.89B |
| Research & development | 1.11B | 1.17B | 1.14B | 1.20B | 1.32B | 1.41B | 1.62B | 2.05B |
| Operating profit | 1.66B | 1.74B | 684.00M | 1.82B | 2.03B | 2.42B | 3.00B | 3.97B |
| Pretax profit | 1.42B | 687.00M | -79.00M | 1.08B | 1.14B | 1.99B | 2.28B | 3.39B |
| Tax | -249.00M | -4.01B | 2.00M | 36.00M | 443.00M | 393.00M | 436.00M | 493.00M |
| Net profit | 1.67B | 4.70B | -82.00M | 1.04B | 698.00M | 1.59B | 1.85B | 2.89B |
| Basic EPS | 1 | 3 | 0 | 1 | 0 | 1 | 1 | 2 |
| Diluted EPS | 1.19 | 3.33 | -0.08 | 0.69 | 0.45 | 1.07 | 1.25 | 1.94 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.66B | 5.06B | 5.07B | 5.29B | 5.20B | 5.44B |
| Gross profit | 3.21B | 3.42B | 3.54B | 3.68B | 3.61B | 3.85B |
| Selling & admin expenses | 1.60B | 1.72B | 1.74B | 1.83B | 1.78B | 1.80B |
| Research & development | 443.00M | 526.00M | 514.00M | 569.00M | 516.00M | 554.00M |
| Operating profit | 937.00M | 943.00M | 1.05B | 1.04B | 1.07B | 1.25B |
| Pretax profit | 805.00M | 941.00M | 939.00M | 700.00M | 1.16B | 1.06B |
| Tax | 133.00M | 146.00M | 183.00M | 30.00M | -176.00M | 155.00M |
| Net profit | 672.00M | 795.00M | 755.00M | 670.00M | 1.34B | 905.00M |
| Basic EPS | 0 | 1 | 1 | 0 | 1 | 1 |
| Diluted EPS | 0.45 | 0.53 | 0.51 | 0.45 | 0.90 | 0.61 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.00B | 4.70B | 6.69B | 6.32B | 5.76B | 6.51B | 6.92B | 8.79B |
| Cash & ST investments | 146.00M | 217.00M | 1.73B | 1.93B | 928.00M | 865.00M | 414.00M | 1.97B |
| Inventory | 1.17B | 1.58B | 1.35B | 1.61B | 1.87B | 2.48B | 2.81B | 2.94B |
| Total assets | 21.00B | 30.57B | 30.78B | 32.23B | 32.47B | 35.14B | 39.40B | 43.67B |
| Total current liabilities | 5.26B | 4.87B | 3.68B | 4.27B | 3.80B | 4.93B | 6.40B | 5.44B |
| Short-term debt | 2.25B | 1.42B | 13.00M | 261.00M | 20.00M | 531.00M | 1.78B | 299.00M |
| Long-term debt | 4.80B | 8.58B | 9.12B | 8.80B | 8.91B | 8.57B | 8.84B | 11.01B |
| Total liabilities | 12,273,000,000.00 | 16,688,000,000.00 | 15,451,000,000.00 | 15,607,000,000.00 | 14,896,000,000.00 | 15,606,000,000.00 | 17,392,000,000.00 | 19,201,000,000.00 |
| Total equity | 8.73B | 13.88B | 15.33B | 16.62B | 17.57B | 19.53B | 22.00B | 24.47B |
| Retained earnings | -6.95B | -2.25B | -2.38B | -1.39B | -750.00M | 819.00M | 2.67B | 5.57B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 7.34B | 7.12B | 8.04B | 8.79B | 8.68B | 7.97B |
| Cash & ST investments | 725.00M | 534.00M | 1.28B | 1.97B | 1.45B | 539.00M |
| Inventory | 2.87B | 2.86B | 2.92B | 2.94B | 3.12B | 3.24B |
| Total assets | 40.14B | 41.56B | 42.71B | 43.67B | 44.35B | 45.22B |
| Total current liabilities | 5.06B | 5.19B | 5.33B | 5.44B | 4.57B | 6.43B |
| Short-term debt | 777.00M | 480.00M | 483.00M | 299.00M | 41.00M | 1.71B |
| Long-term debt | 10.41B | 10.98B | 10.99B | 11.01B | 10.86B | 10.79B |
| Total liabilities | 17,694,000,000.00 | 18,906,000,000.00 | 19,077,000,000.00 | 19,201,000,000.00 | 18,247,000,000.00 | 20,044,000,000.00 |
| Total equity | 22.45B | 22.65B | 23.63B | 24.47B | 26.10B | 25.17B |
| Retained earnings | 3.35B | 4.14B | 4.90B | 5.57B | 6.91B | 7.82B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 310.00M | 1.84B | 1.51B | 1.87B | 1.53B | 2.50B | 3.44B | 4.53B |
| Depreciation & amortization | 894.00M | 1.01B | 1.12B | 1.09B | 1.14B | 1.20B | 1.27B | 1.37B |
| Free cash flow | -178.00M | 1.38B | 1.13B | 1.32B | 914.00M | 1.70B | 2.37B | 3.40B |
| Dividends paid | 0 | 0 | -28.00M | -55.00M | -55.00M | -28.00M | 0 | -- |
| Stock buybacks / issuance | 0 | 0 | 440.00M | -- | -- | -- | -- | -- |
| Ending cash balance | 829.00M | 607.00M | 2.00B | 2.17B | 1.13B | 1.06B | 606.00M | 2.15B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 541.00M | 1.29B | 1.34B | 1.36B | 348.00M | 1.47B |
| Depreciation & amortization | 325.00M | 336.00M | 342.00M | 365.00M | 351.00M | 355.00M |
| Free cash flow | 277.00M | 1.04B | 1.15B | 939.00M | 171.00M | -451.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 919.00M | 741.00M | 1.48B | 2.15B | 1.64B | 753.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 21.24 | 41.59 | -0.79 | 6.17 | 3.75 | 8.52 | 9.03 | 12.60 |
| ROA %i | 8.35 | 18.23 | -0.37 | 3.13 | 1.98 | 4.64 | 4.97 | 6.98 |
| ROIC %i | 13.00 | 25.17 | 0.95 | 5.15 | 3.49 | 6.35 | 6.53 | 9.25 |
| 5-year avg ROE %i | 4.50 | 13.18 | 13.77 | 13.94 | 14.39 | 11.85 | 5.34 | 8.01 |
| EBIT margin %i | 16.93 | 10.81 | 2.84 | 11.92 | 12.70 | 15.80 | 15.45 | 18.60 |
| FCF / sales %i | -- | 11.42 | 9.95 | 11.07 | 7.40 | 11.96 | 14.12 | 16.96 |
| Current ratioi | 0.76 | 0.97 | 1.82 | 1.48 | 1.51 | 1.32 | 1.08 | 1.62 |
| Quick ratioi | 0.34 | 0.42 | 0.89 | 0.87 | 0.76 | 0.63 | 0.46 | 0.90 |
| Debt / assetsi | 33.60 | 33.62 | 30.99 | 29.32 | 28.59 | 27.02 | 27.28 | 26.19 |
| LT debt / equityi | 55.05 | 63.85 | 62.15 | 55.28 | 52.70 | 46.48 | 41.19 | 45.96 |
| Interest coveragei | 6.90 | 2.45 | 0.78 | 4.16 | 3.43 | 8.49 | 8.48 | 10.70 |
| Revenue CAGR (3Y) %i | 9.52 | 8.58 | 3.09 | 6.57 | 5.71 | 12.83 | 12.10 | 16.54 |
| Net income CAGR (3Y) %i | -- | 138.37 | -- | -14.59 | -47.04 | -- | 21.21 | 60.72 |
| FCF CAGR (3Y) %i | -- | 26.83 | 5.07 | -- | -12.73 | 14.58 | 21.58 | 55.01 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 9.64 | 11.71 | 12.66 | 12.60 | 14.83 | 15.52 |
| ROA %i | 5.29 | 6.37 | 6.91 | 6.98 | 8.44 | 8.47 |
| ROIC %i | 7.07 | 8.46 | 9.14 | 9.25 | 11.03 | 11.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.93 | 18.01 | 18.65 | 18.60 | 19.88 | 20.12 |
| FCF / sales %i | 15.51 | 17.49 | 18.75 | 16.96 | 16.00 | 8.60 |
| Current ratioi | 1.45 | 1.37 | 1.51 | 1.62 | 1.90 | 1.24 |
| Quick ratioi | 0.68 | 0.65 | 0.77 | 0.90 | 0.98 | 0.56 |
| Debt / assetsi | 29.17 | 28.94 | 28.21 | 26.19 | 24.87 | 27.92 |
| LT debt / equityi | 49.21 | 51.51 | 49.43 | 45.96 | 42.48 | 43.78 |
| Interest coveragei | 8.80 | 10.06 | 10.65 | 10.70 | 11.48 | 11.64 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Cardiovascular is the largest reported line at 66.56% of revenue, across 3 reported segments.
- MedSurg follows at 33.41%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Cardiovascular66.56%
MedSurg33.41%
Quote time 2026-10-08 07:00:10 · For reference only, not investment advice and not tailored to your situation.